CD274 and triple-negative breast carcinoma: PD-L1 inhibitors, such as atezolizumab in combination with chemotherapy, have demonstrated an overall response rate (ORR) of 29% in triple-negative breast cancer patients with bone metastasis, with the PD-L1+ subgroup showing improved OS of 25 months (290).